These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12003404)

  • 1. Is bezafibrate histologically effective for primary biliary cirrhosis?
    Yano K; Kato H; Morita S; Takahara O; Ishibashi H; Furukawa R
    Am J Gastroenterol; 2002 Apr; 97(4):1075-7. PubMed ID: 12003404
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel treatment for refractory primary biliary cirrhosis?
    Miyaguchi S; Ebinuma H; Imaeda H; Nitta Y; Watanabe T; Saito H; Ishii H
    Hepatogastroenterology; 2000; 47(36):1518-21. PubMed ID: 11148991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New weapon for primary biliary cirrhosis from Japan.
    Zeniya M
    J Gastroenterol; 2003; 38(6):619-20. PubMed ID: 12858848
    [No Abstract]   [Full Text] [Related]  

  • 4. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy.
    Kurihara T; Maeda A; Shigemoto M; Yamashita K; Hashimoto E
    Am J Gastroenterol; 2002 Jan; 97(1):212-4. PubMed ID: 11808959
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.
    Akbar SM; Furukawa S; Nakanishi S; Abe M; Horiike N; Onji M
    J Gastroenterol; 2005 Feb; 40(2):157-63. PubMed ID: 15770399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezafibrate treatment: a new medical approach for PBC patients?
    Kanda T; Yokosuka O; Imazeki F; Saisho H
    J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.
    Nakai S; Masaki T; Kurokohchi K; Deguchi A; Nishioka M
    Am J Gastroenterol; 2000 Jan; 95(1):326-7. PubMed ID: 10638623
    [No Abstract]   [Full Text] [Related]  

  • 8. [Possibilities in the treatment of primary biliary cirrhosis].
    Lengyel G; Tulassay Z
    Orv Hetil; 2005 Jun; 146(23):1245-9. PubMed ID: 15988919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate treatment in patients with primary biliary cirrhosis.
    Ohira H; Sato Y; Ueno T; Sata M
    Am J Gastroenterol; 2002 Aug; 97(8):2147-9. PubMed ID: 12190200
    [No Abstract]   [Full Text] [Related]  

  • 10. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid.
    Kurihara T; Niimi A; Maeda A; Shigemoto M; Yamashita K
    Am J Gastroenterol; 2000 Oct; 95(10):2990-2. PubMed ID: 11051391
    [No Abstract]   [Full Text] [Related]  

  • 11. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.
    Kita R; Takamatsu S; Kimura T; Kokuryu H; Osaki Y; Tomono N
    J Gastroenterol; 2006 Jul; 41(7):686-92. PubMed ID: 16933007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis.
    Ohmoto K; Yoshioka N; Yamamoto S
    J Gastroenterol; 2006 May; 41(5):502-3. PubMed ID: 16799896
    [No Abstract]   [Full Text] [Related]  

  • 13. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).
    Kita R; Kita-Sasai Y; Hanaoka I; Kimura T; Kokuryu H; Takamatsu S; Osaki Y; Tomono N; Hachiya T; Shimizu T
    Am J Gastroenterol; 2002 Jul; 97(7):1849-51. PubMed ID: 12135056
    [No Abstract]   [Full Text] [Related]  

  • 14. Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C.
    Kurihara T; Niimi A; Maeda A; Shigemoto M; Yamashita K
    Am J Gastroenterol; 2001 May; 96(5):1659-60. PubMed ID: 11374732
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C.
    Fujita N; Kaito M; Tanaka H; Horiike S; Adachi Y
    Am J Gastroenterol; 2004 Nov; 99(11):2280. PubMed ID: 15555013
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of bezafibrate in primary biliary cirrhosis: a pilot study.
    Ohmoto K; Mitsui Y; Yamamoto S
    Liver; 2001 Jun; 21(3):223-4. PubMed ID: 11422787
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Walker LJ; Newton J; Jones DE; Bassendine MF
    Hepatology; 2009 Jan; 49(1):337-8; author reply 338. PubMed ID: 19035342
    [No Abstract]   [Full Text] [Related]  

  • 18. No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!
    Halliday JS; Chapman RW
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1345-6. PubMed ID: 21884243
    [No Abstract]   [Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
    Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
    Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies in primary biliary cirrhosis.
    Taal BG
    Neth J Med; 1981; 24 Suppl 1():1-30. PubMed ID: 7322249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.